Pharma Medical News

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

New Data Show Once-Daily INTUNIV Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners’ ADHD Rating Scale
Shire, 11/02/09

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV Extended Release Tablets, at a major psychiatric medical meeting. The primary objective of this study was to assess the change from baseline on the oppositional subscale of the Conners' Parent Rating Scale–Revised: Long Form in patients ages 6 to 12 with a primary diagnosis of Attention–Deficit/Hyperactivity Disorder with the presence of oppositional symptoms at baseline. INTUNIV met the primary objective demonstrating significant efficacy in reducing symptoms as measured by the oppositional subscale.

<< Previous
Shire Reports Tolerability and Clinical Effects Results of...

Next >>
Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b...